EU Drugs Agency Convenes Cannabis Mental Health Forum
The European Monitoring Centre for Drugs and Drug Addiction hosted a closed-door expert roundtable on cannabis use and psychiatric outcomes.
A counselor facilitating a group therapy session in a modern indoor setting.
Agency Scope and Mandate
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) organized the forum under its 2025-2027 work program, which prioritizes harm-reduction frameworks for psychoactive substances. The agency tracks cannabis use patterns in 27 EU member states plus Norway and Turkey. According to EMCDDA's 2025 European Drug Report, 22.6 million adults used cannabis in the past year, a 4.1% increase from 2024.
The forum didn't produce binding recommendations. It served as a data-exchange session ahead of the agency's planned 2027 technical report on cannabis and psychosis risk.
Mental Health Evidence Under Review
Participants examined longitudinal cohort studies showing elevated rates of psychotic disorders among daily high-THC users, with particular focus on populations under age 25. The agency's briefing materials cited a 2025 Lancet Psychiatry meta-analysis finding a 2.8-fold increased risk of schizophrenia-spectrum disorders in daily users versus non-users.
Researchers also reviewed contradictory findings on anxiety and depression outcomes. Some national registries show therapeutic benefit in palliative-care settings. Others document dose-dependent harm in adolescent cohorts. The data gaps are widest for CBD-dominant products and synthetic cannabinoids, both underrepresented in EU surveillance systems.
For broader context on research developments, see the CannIntel topic hub on cannabis and mental health.
Policy Implications for Member States
The forum's timing coincides with Germany's adult-use rollout and ongoing decriminalization debates in France, Italy, and the Czech Republic. Germany's Cannabis Act took effect in April 2024, permitting home cultivation and nonprofit social clubs. Early psychiatric admissions data from Berlin and Munich hospitals are under review but haven't been published yet.
France's National Assembly tabled a decriminalization bill in June 2026 after public health committees flagged insufficient mental health screening protocols. Italy's regional pilot programs continue to operate under 2025 legislative decrees, with mandatory psychiatric referrals for users under 21.
Summary findings arrive in Q1 2027. Member states aren't obligated to adopt any resulting guidance, but the agency's technical reports typically inform national drug strategies and EU funding allocations for harm-reduction programs.
Frequently asked questions
What is the EMCDDA?
The European Monitoring Centre for Drugs and Drug Addiction tracks substance use patterns and public health outcomes across 27 EU member states plus Norway and Turkey. It produces technical reports that inform national drug policy but does not set binding regulations.
What mental health risks did the forum examine?
Participants reviewed longitudinal studies showing a 2.8-fold increased risk of schizophrenia-spectrum disorders in daily cannabis users versus non-users, particularly in populations under age 25. Evidence on anxiety and depression outcomes remains mixed.
Will the forum produce new cannabis regulations?
No. The forum was a data-exchange session. The EMCDDA will publish summary findings in Q1 2027, but member states are not required to adopt any resulting guidance.
How does this relate to Germany's adult-use program?
Germany's Cannabis Act took effect in April 2024. Early psychiatric admissions data from German hospitals are under review but not yet published. The forum's timing reflects ongoing policy debates across the EU.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Medical
First National Study Counts 110,000 Medical Cannabis Caregivers
New research provides the first comprehensive estimate of designated caregivers dispensing medical cannabis to patients across U.S. state programs.
New Study Links Cannabis Use to Increased Seizures in Epilepsy Patients
Research challenges long-held assumptions about cannabis as seizure therapy for certain patient populations.
Medical Cannabis Improves Symptoms in 80% of Cancer Patients, Study Finds
University of Kentucky researchers surveyed 237 radiation patients and found four in five reported relief from pain, nausea, and anxiety.
More from the newsroom
DEA Halts Marijuana Rescheduling Hearing Over GAO Report
Administrative law judge pauses proceedings pending Government Accountability Office review of DEA's Schedule III proposal.
LA Mayoral Frontrunner Nithya Raman Unveils Fix for 'Broken' Cannabis Market
City Councilmember proposes sweeping reforms to the largest municipal cannabis market in the United States.
Virginia Releases Draft Adult-Use Cannabis Regulations With Key Gaps
The Cannabis Control Authority published its first regulatory framework for adult-use sales, but critical licensing and equity provisions remain undefined.